Navigation Links
Natural anti-viral enzyme helps keep cancer cells alive, researchers find

A molecule that cells normally use to fight viruses is also involved in keeping cancer cells alive, researchers at UT Southwestern Medical Center have discovered.

The anti-viral molecule, called TBK-1, was found to be essential for cancer cells to live, so blocking it might point to a treatment for fighting cancer, the researchers report in today's issue of Cell.

"We got the surprise that this mechanism is involved in cancer cell survival, even though it's normally involved in immune response," said Dr. Michael White, associate professor of cell biology. "We found something a little bit different ?an Achilles' heel of cancer cells that's apparently broadly conserved among many types of solid tumors."

Using cultured human cells, the researchers set out to study enzymes known to be involved in keeping cancer cells alive and proliferating. They soon narrowed the focus to one called RalB. This molecule is part of the Ras family of enzymes, which are mutated in 30 percent of all cancers and in 90 percent of pancreatic cancers.

The UT Southwestern scientists knew that RalB interacts with a protein complex called the exocyst, which helps small secretory packets in cells fuse to the cell membrane. The team isolated this complex, then chemically analyzed the proteins attached to it.

One protein they found on the exocyst, TBK-1, is known to be involved in cells' anti-viral response.

"There was nothing known about that mechanism to suggest how TBK-1 could drive cancer cell survival," Dr. White said.

The researchers found that TBK-1 is turned off in healthy cells unless the immune response is stimulated but was always active in the cancerous cells they studied. When they blocked the function of TBK-1 in both the cancerous and healthy cells, cancer cells died while healthy cells survived.

A German research team has studied clinical samples of tumors and found elevated levels of TBK-1, Dr. White said.


'"/>

Source:UT Southwestern Medical Center


Page: 1 2

Related biology news :

1. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
2. Natural Killers Could Lead to New Hepatitis Treatments
3. Natural tumor suppressor in body discovered by UCSD medical researchers
4. Naturally occurring asbestos linked to lung cancer
5. Natural compound from pond scum shows potential activity against Alzheimers
6. Natural selection at single gene demonstrated
7. Natural vitamin E tocotrienol reaches blood at protective levels
8. Natural pine bark extract relieves muscle cramp and pain in athletes and diabetics
9. Natural protein stops deadly human brain cancer in mice
10. Natural polyester makes new sutures stronger, safer
11. Natural gut hormone offers hope for new obesity drug

Post Your Comments:
(Date:11/8/2009)...E, Ind. - Researchers at Purdue University have di...e fibers in spinal cord injuries using nano-sphere...ter an accident. , The synthetic "copolymer mice...s in diameter, or roughly 100 times smaller than t...ave been studying how to deliver drugs for cancer ...
(Date:11/6/2009)...stration is now open for the Society of Interventi...logy (IO) Therapies" Webinar, which will provide t...r treatment of liver tumors, kidney tumor ablation...zation of physicians, scientists and allied health...h through pioneering advances in image-guided ther...
(Date:11/6/2009).... 6 Auburn Hills, MI-based Law Enf...nstalling its locker system and patent-pending Bio.... Department of Health and Human Services, Nationa.... The locker system will support the NIH,s entire...ur nation,s medical research agency. The project ...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 1New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 2New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 4New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 5New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 6New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 7New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 8New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 9New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 10New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 11New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 12New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 13New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 14New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 15New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 16New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 17New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 18New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 19New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 20New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 21New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 22Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
...which trauma and burn patients are most likely to ...wide range of experimental clinical settings ?an i...outinely used in emergency rooms and intensive car...in the Proceedings of the National Academy of Scie...ng the University of Florida, describe how they we...
...iego (UCSD) have found that Lafora disease, an inh...he age of 30, can be caused by mutations in a gene...aforin. These findings are reported in the current...ciences (PNAS). , Lafora disease is characterized ..., followed by an initial seizure in the second dec...
...cancers from Nigeria, Senegal and North America ha...kely to be diagnosed with a more virulent form of ...searchers from the University of Chicago, working ...geria and the University of North Carolina, found ...ferent pattern of gene expression. Tumors from Afr...
Other Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
(Date:11/6/2009)..., SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCal... Completed transfer of Qutenza(TM) E.U. Marketing ...e significant progress in commercial readiness act...les; Senior Director, Marketing; and Director, Com...to board as director and Audit Committee chairman ...
(Date:11/6/2009)..., CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncol...tics" or the "Company") today announced updated re...N(R) in patients with sarcomas metastatic to the l...nnective Tissue Oncology Society Meeting held in M... poster presentation, entitled "A Phase II Study o...
(Date:11/6/2009)... The agenda for Arrowhead&r...ference, which is set to take place on February 22...this three day conference we will highlight key is...peakers to share their experiences. , ...009 -- The agenda for Arrowhead’s 2010 Pers...
(Date:11/5/2009)..., GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCal...d its financial results for the third quarter ende...f $3.6 million ($0.04 per share) for the three mon...s of $6.8 million ($0.08 per share) in the compara...tember 30, 2009, GenVec,s net loss was $14.1 milli...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...he Maryland Stem Cell Research,Commission (Commiss... for,new post-doctoral fellowship grants under RFA...applications from pre-doctoral students and post-,...translational research on,all types of human stem ... fellowships will be funded with each,fellowship b...
...Raptor,Pharmaceuticals Corp. ("Raptor" or the "Com... that its clinical development division, Bennu,Pha...al product candidate,EC Cysteamine. Bennu received... developed by clinical scientists at the Universit... way of its acquisition by,merger of Encode Pharma...
... 17 , - New Deal Provides a Further Opportunity f... Oxford Genome Sciences (UK) Ltd "OGeS" announces...oration with Amgen to discover, develop and,commer...ment of cancer.,This new collaboration will enable...human therapeutic antibodies (mAbs) in cancer base...
Other Biology Technology:Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
Anti-Chloride Channel, CLC-2 Polyclonal Antibody, Unconjugated from CHEMICON
... 2, Monoclonal Antibody, Unconjugated Applicati...ICC: Use at an assay dependent dilution. WB: Use a...ion is determined using a whole extract of rat bra... in other applications. Optimal dilutions/concent...
Anti-TWIK-2 (Kcnk6, TOSS) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: